503537-22-2

Upstream product

• 159706-87-3 4-benzyl-3-(4-fluorophenyl)morpholin-2-one 
• 503537-21-1 (S)-2-Allyl-4-benzyl-3-(4-fluoro-phenyl)-morpholin-2-ol 

Downstream Products

• 195605-26-6 (5S,10S)-9-Benzyl-10-(4-fluoro-phenyl)-3-[2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl)-phenyl]-1,6-dioxa-9-aza-spiro[4.5]dec-3-ene 
• 195605-08-4 (3S,5S,10S)-10-(4-Fluoro-phenyl)-3-[2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl)-phenyl]-1,6-dioxa-9-aza-spiro[4.5]decane 
• 180534-17-2 Trifluoro-methanesulfonic acid (5R,10S)-9-benzyl-10-(4-fluoro-phenyl)-1,6-dioxa-9-aza-spiro[4.5]dec-3-en-3-yl ester 
• 180533-39-5 (3S,5S,10S)-10-(4-Fluoro-phenyl)-3-(2-methoxy-phenyl)-1,6-dioxa-9-aza-spiro[4.5]decane 

Relevant academic research and scientific papers

Spirocyclic NK1 antagonists I: [4.5] and [5.5]-Spiroketals

A series of novel spiroketal-based NK1 antagonists is described. The effect of modifications to the spiroether ring and aromatic substituents are discussed, leading to the identification of compounds with high affinity and excellent CNS penetration.